SG11202007508TA - Farber disease markers and uses thereof - Google Patents

Farber disease markers and uses thereof

Info

Publication number
SG11202007508TA
SG11202007508TA SG11202007508TA SG11202007508TA SG11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA
Authority
SG
Singapore
Prior art keywords
disease markers
farber disease
farber
markers
disease
Prior art date
Application number
SG11202007508TA
Other languages
English (en)
Inventor
Christine Coquery
Brante Sampey
Original Assignee
Enzyvant Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzyvant Therapeutics Gmbh filed Critical Enzyvant Therapeutics Gmbh
Publication of SG11202007508TA publication Critical patent/SG11202007508TA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023Ceramidase (3.5.1.23)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202007508TA 2018-03-27 2019-03-22 Farber disease markers and uses thereof SG11202007508TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648775P 2018-03-27 2018-03-27
PCT/IB2019/000290 WO2019186272A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Publications (1)

Publication Number Publication Date
SG11202007508TA true SG11202007508TA (en) 2020-09-29

Family

ID=66530353

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007508TA SG11202007508TA (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Country Status (15)

Country Link
EP (1) EP3775924A1 (https=)
JP (2) JP2021516757A (https=)
KR (2) KR20200136367A (https=)
CN (2) CN111971562A (https=)
AU (1) AU2019244477A1 (https=)
BR (1) BR112020016435A2 (https=)
CA (1) CA3090354A1 (https=)
CL (1) CL2020002105A1 (https=)
CO (1) CO2020010043A2 (https=)
IL (2) IL311212A (https=)
MX (1) MX2020008377A (https=)
PH (1) PH12020551206A1 (https=)
RU (1) RU2020119065A (https=)
SG (1) SG11202007508TA (https=)
WO (1) WO2019186272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152532A1 (en) * 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
US20240180982A1 (en) * 2021-03-29 2024-06-06 University College Cardiff Consultants Limited Modified adenovirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995001164A1 (en) 1993-06-30 1995-01-12 Genentech, Inc. Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CA2905449C (en) 2013-03-14 2024-09-10 Icahn School Of Medicine At Mount Sinai THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE
EP3115786A1 (en) * 2015-07-08 2017-01-11 Centogene AG Method for the diagnosis of farber's disease

Also Published As

Publication number Publication date
CN111971562A (zh) 2020-11-20
RU2020119065A (ru) 2022-04-27
JP2021516757A (ja) 2021-07-08
WO2019186272A1 (en) 2019-10-03
EP3775924A1 (en) 2021-02-17
AU2019244477A1 (en) 2020-06-25
CN118112249A (zh) 2024-05-31
IL276420A (en) 2020-09-30
JP2023159164A (ja) 2023-10-31
CA3090354A1 (en) 2019-10-03
MX2020008377A (es) 2020-09-25
PH12020551206A1 (en) 2021-04-19
BR112020016435A2 (pt) 2020-12-15
CL2020002105A1 (es) 2020-12-04
IL311212A (en) 2024-05-01
KR20200136367A (ko) 2020-12-07
CO2020010043A2 (es) 2020-11-10
KR20240111011A (ko) 2024-07-16

Similar Documents

Publication Publication Date Title
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
IL277502A (en) Compounds and uses for them
IL277791A (en) HSP90 targeting conjugates and their formulations
EP3394289C0 (en) MICROBIAL MARKER OF SPONDYLATRITIS
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL278142A (en) Antiproliferative compounds and their uses
IL278881A (en) Cannabinoids and their use
IL287503A (en) Thio-semicarbazide compounds and their use
LT3336196T (lt) Kviečių žymenys ir jų naudojimas
SG11202009242RA (en) Short conjugated oligoelectrolytes and uses thereof
IL279483A (en) Cyanotriazole compounds and their uses
IL276420A (en) Suburb disease markers and their uses
ZA202106713B (en) Novel pathological marker and uses thereof
GB201701480D0 (en) Disease resistance
GB201803387D0 (en) Disease detection
HK40046537A (en) Farber disease markers and uses thereof
GB201818904D0 (en) New formulations and methods
GB2563258B (en) Self-erecting penis
GB201717738D0 (en) Well design and associated well structures
EP3344986A4 (en) MARKERS OF CORONARY DISEASE AND USES THEREOF
GB201803252D0 (en) Markers and uses thereof
GB2594638B (en) Pancreas disease virus markers
GB201820629D0 (en) Marker
SG11202011823SA (en) Activator-nucleator formulations